Starting a Statin: Who, When, and How to Talk About It

Who actually needs a statin, and how to start that conversation

A statin is clearly indicated for anyone with known cardiovascular disease, diabetes with additional risk factors, or an LDL of 190 or higher. For everyone else, the decision comes down to a 10-year (and increasingly, 30-year) risk estimate, not just an LDL number on its own. Getting the risk conversation right matters as much as getting the prescription right, because a patient who understands why is a patient who actually takes it.

The four groups who need a statin without much debate

Start here, because these patients don't need a risk calculator to make the decision:

• Known cardiovascular disease (secondary prevention): prior MI, stroke, or established ASCVD
• LDL 190 mg/dL or higher, regardless of other risk factors
• Diabetes, ages 40-75, especially with additional risk factors present
• High estimated risk on a validated calculator, discussed below

If your patient fits one of the first three, the conversation is about starting, not about whether.

For everyone else: risk estimate, not LDL alone

The newest guidance uses a 10- and 30-year risk tool (PREVENT-ASCVD) for adults 30-79 without known cardiovascular disease, and it tends to run lower than older risk calculators, which had overestimated 10-year risk for many patients. Broadly, low estimated risk favors lifestyle counseling over a prescription, high estimated risk favors starting, and there's a real middle band in between where the calculator alone does not make the decision for you.

That middle band is where risk-enhancing factors do their work: family history of premature cardiovascular disease, chronic inflammatory conditions, elevated Lp(a) if known, and metabolic risk factors beyond diabetes. Weighing those factors against the calculator output for a specific patient, and knowing where your own threshold for "start" versus "watch" actually sits, is clinical judgment I work through case by case inside Mastery.

How to actually have the conversation

The clinical indication is only half the visit. The other half is whether the patient walks out understanding why, because that's what determines whether they still take it in six months.

• Lead with the risk, not the drug. "Your risk of a heart attack or stroke over the next 10 years is about X%. A statin lowers that." That framing lands better than starting with side effects or dosing.
• Name the actual benefit in plain terms. Statins lower LDL and reduce cardiovascular events. They are not a weight-loss drug, a cure, or a lifetime sentence to feeling sick, and it's worth saying that directly since patients often arrive with strong opinions from social media.
• Address muscle aches before the patient brings it up. Most people who think they can't tolerate statins can tolerate a different one, or a lower dose, or every-other-day dosing. Say this up front so the first ache doesn't end the conversation.
• Set the follow-up. Recheck a lipid panel at 4 to 12 weeks after starting to confirm response, then annually once stable.

What to actually prescribe

The March 2026 ACC/AHA dyslipidemia guideline moved this back to explicit numbers. Instead of picking a statin intensity bucket and calling it done once the patient tolerates it, pick the statin and dose that gets the patient to an explicit LDL-C (and non-HDL-C) target, and intensify if the follow-up panel doesn't get there.

• General primary prevention: LDL-C <100 mg/dL (non-HDL-C <130 mg/dL).
• Higher-risk primary prevention (multiple risk enhancers, high CAC score): LDL-C <70 mg/dL.
• Secondary prevention or ASCVD-risk-equivalent (established ASCVD, LDL 190+, CAC 1000 or higher): LDL-C <55 mg/dL.

Moderate-intensity statins (roughly 30-49% LDL reduction) are still a reasonable place to start for most primary prevention patients, that part hasn't changed. What's different is the follow-up: if the 4-to-12-week recheck doesn't hit the target for that patient's risk tier, the next step is intensifying, higher dose, adding ezetimibe, or a PCSK9 inhibitor for very high-risk patients, not just noting the number and moving on. High-intensity statins (50%+ reduction) are still the starting point for secondary prevention, very high risk, or LDL 190+, since those patients are unlikely to hit target on a moderate dose anyway.

When to worry: a quick reference

Frequently asked questions

Does every patient with high cholesterol need a statin?
No. LDL alone is not the deciding factor for most patients. Outside of an LDL of 190+, known cardiovascular disease, or diabetes with risk factors, the decision is based on a 10-year (and 30-year) risk estimate, not the cholesterol number by itself.

What risk calculator should I use to decide on a statin?
The current guideline uses PREVENT-ASCVD for adults 30-79 without known cardiovascular disease. It estimates both 10- and 30-year risk and tends to run lower than older risk models, which had overestimated risk for many patients.

What 10-year risk percentage means a statin should be started?
Low estimated risk generally favors lifestyle counseling over a prescription, and high estimated risk generally favors starting. There's a real middle band in between where the calculator alone doesn't decide it, and that's where risk-enhancing factors and clinical judgment take over.

Should I start with a high-intensity or moderate-intensity statin?
Moderate-intensity is still a reasonable starting point for most primary prevention patients. But the goal now is an explicit LDL-C target, typically <100 mg/dL for general primary prevention, <70 mg/dL for higher-risk primary prevention, or <55 mg/dL for secondary prevention or ASCVD-risk-equivalent patients, not just picking an intensity and stopping there. High-intensity is still the starting point for secondary prevention, very high risk, or an LDL of 190 or higher.

What should I tell a patient worried about statin side effects?
Address muscle aches proactively rather than waiting for the patient to bring it up. Most people who believe they can't tolerate statins can tolerate a different statin, a lower dose, or a different dosing schedule.

Source: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia, Circulation, March 2026.

Written by Allison Sowders, MSN, APRN, FNP-BC, a practicing primary care nurse practitioner and founder of Nurse Practitioner Mentor. Reviewed September 2026.

If a patient has already tried a statin and stopped, the workup is different. See Statin Intolerance and Overview of Hyperlipidemia in Primary Care for more. Inside the Primary Care Clinical Mastery Program I teach the full cardiovascular risk and medication decision system, so you're not re-deriving the risk conversation from scratch every visit, with CE hours included.